Patients who used GLP-1 medications before bariatric surgery lost about the same amount of weight one year afterward as patients who went straight to the operating room, according to a study published in JAMA Surgery. Prior users lost 24 percent of their total body weight. Non-users lost 25 percent. The difference was not statistically significant.
The finding matters because clinicians expected something different and had planned accordingly. Bariatric procedures work partly by raising the body's own GLP-1 levels, which raised a reasonable question about whether patients whose GLP-1 pathways had already been stimulated by medication would get less out of surgery.
In this cohort, they did not. Patients who had presumably already lost weight on medication still achieved substantial additional weight loss after their operation.
Inside the UCSF Analysis
Researchers at the University of California, San Francisco, led by Jonathan Carter, reviewed 383 primary bariatric procedures performed at a single center between 2022 and 2024.
Of those patients, 92 had used a GLP-1 medication before surgery, primarily semaglutide. The remaining 291 had never used the drug class. Sleeve gastrectomy accounted for the large majority of procedures in the study.
The two groups were broadly similar in age, body mass index, sex, and other characteristics. Multivariable regression confirmed that preoperative medication use did not predict total weight loss. Greater weight loss was associated with a higher preoperative body mass index and male sex, while diabetes and sleeve gastrectomy were associated with less weight loss.
Beyond weight, the researchers found no significant differences in diabetes control, postoperative complications, length of hospital stay, or emergency department visits.
That last set of findings is arguably the most immediately useful. Surgical teams have been navigating questions about GLP-1 use and perioperative risk, particularly around delayed gastric emptying and anesthesia safety, and this study found no signal of worse outcomes.
The Broader Evidence Is Not Unanimous
A single-center study does not settle a question, and this one lands in a literature that has produced mixed results.
Two other recent retrospective analyses similarly found no difference in 12-month postoperative weight loss between GLP-1 users and non-users.
But at least one analysis pointed the other way. In a matched study at Brigham and Women's Hospital, 182 patients treated with semaglutide before surgery were compared against 182 controls. Postoperative weight loss at 12 months was 21 percent in the semaglutide group and 26 percent in the control group, a statistically significant difference. Combined weight loss, counting the medication phase, was higher in the semaglutide group at three months but did not differ thereafter, and the researchers found no benefit in safety outcomes either.
Separately, research presented at the American Society for Metabolic and Bariatric Surgery annual meeting in May 2026 by NYU Grossman School of Medicine investigators drew on records from more than 6,700 patients prescribed GLP-1 medications in the six months before surgery. Those patients lost about 8 percent of body weight on medication, then reached more than 25 percent total after gastric bypass and about 20 percent after sleeve gastrectomy. Patients who went directly to surgery lost about 2 to 3 percent more after their procedures. That work was presented at a conference and should be treated as preliminary until published.
Taken together, the picture is that preoperative GLP-1 use does not appear to substantially compromise surgical results, with some studies showing a small disadvantage and others showing none.
Reading This Before Choosing Between Medication and Surgery
The practical framing that emerges from this research is that medication and surgery are not competitors. Patients increasingly use both in sequence over years.
Someone currently on a GLP-1 who is considering surgery does not have a reason from this study to expect a worse surgical outcome. Someone who has plateaued on medication is not disqualifying themselves from surgical benefit by having tried it first.
What patients should not take from this is a treatment decision. This is a retrospective study at one center, with 92 patients in the exposure group and no randomization. It cannot establish cause. Patients on GLP-1 medications should follow their surgical team's specific perioperative instructions, which typically address when to hold doses before anesthesia, and should not adjust any medication independently.
The NYU work raised a separate consideration worth knowing. Patients who used GLP-1s before surgery were more likely to resume them afterward, 57.4 percent after sleeve gastrectomy and 44.1 percent after gastric bypass in the first year, with roughly two-thirds of all patients back on the drugs by three years. That has cost implications that outlast the surgical recovery.
The Cost and Coverage Layer
For most households, the financial question is more decisive than the clinical one.
Bariatric surgery is covered by most commercial plans and by Medicare when documented criteria are met, typically involving body mass index thresholds, obesity-related conditions, and supervised weight-management attempts. Coverage requirements vary and should be confirmed in writing before scheduling.
GLP-1 coverage remains far more variable. MedicalDaily has reported on the Medicare GLP-1 Bridge Program, which launched on July 1, 2026, with a $50 monthly copay for eligible Part D enrollees, but is set to expire at the end of 2027, with no successor confirmed. State Medicaid coverage for obesity indications has narrowed rather than expanded.
Patients who expect to need medication after surgery should factor that into planning rather than assuming coverage will hold.
Larger multicenter analyses and prospective studies are needed to determine whether GLP-1 dosing, duration of use, and the amount of weight lost before surgery change outcomes. None of the existing studies answered those questions, and several authors noted them explicitly as gaps.
Patients making decisions now should have this conversation directly with a bariatric program, ideally one that offers both medical and surgical obesity treatment, so the comparison is made without a thumb on the scale.
Key Questions Answered
Does taking a GLP-1 before surgery reduce how much weight surgery removes?
In this study, no. Prior users lost 24 percent of total body weight at 12 months, and non-users lost 25 percent, a difference that was not statistically significant.
Why did clinicians expect a difference?
Bariatric surgery works partly by increasing the body's own GLP-1 levels. That raised a question about whether patients already treated with GLP-1 drugs would respond less to the operation.
Did GLP-1 use raise surgical risk?
The study found no significant differences in complications, length of stay, or emergency department visits between the two groups.
Do all studies agree?
No. Several found no difference, but a matched analysis of 182 patients found significantly less postoperative weight loss among those treated with semaglutide first. The evidence is mixed.
How strong is this study?
It is retrospective, single-center, and included 92 patients in the GLP-1 group. It shows an association, not causation, and larger multicenter research is needed.
Should someone stop their GLP-1 before surgery?
Only on the instruction of their surgical team. Perioperative protocols address when to hold doses before anesthesia, and patients should not adjust medication on their own.
Will insurance cover GLP-1 drugs after surgery?
Coverage varies widely. Medicare's Bridge Program expires at the end of 2027, and state Medicaid coverage for obesity has narrowed. Patients should verify coverage before assuming continued access.
